BACKGROUND: The study objective was to assess differences in demographics and travel health challenges between youths ≤18 years old traveling internationally to visit friends and relatives (VFRs) compared with those traveling for other purposes (non-VFR). METHODS: The Boston Area Travel Medicine Network consists of 5 clinics collecting anonymous data from international pretravel consultations. Data on all travelers ≤18 years of age seen between January 2008 and July 2010 were used. VFRs were compared with non-VFRs on demographics, primary language, trip characteristics, travel vaccinations administered, malaria prophylaxis and antidiarrheal medications prescribed. RESULTS: Thirty-five percent (610/1731) listed VFR as their purpose of travel. Almost half of VFRs were <5 (46%) years old compared with <5% of non-VFRs. Thirty percent of US-born VFRs with foreign-born parents were ≤2 years compared with 4% of foreign-born VFR children and 3% of US-born VFRs with US-born parents. More VFRs than non-VFRs planned travel to countries that were yellow fever holoendemic, had malaria risk and were high-risk for typhoid (44% versus 20%, 39% versus 12%, 25% versus 15%, P < 0.01). VFRs were less likely than non-VFRs to be prescribed atovaquone-proguanil (adjusted prevalence ratio = 0.57, confidence interval = 0.44-0.72) and to have had an antidiarrheal medication prescribed (adjusted prevalence ratio = 0.68, confidence interval = 0.60-0.75). CONCLUSIONS: To reduce travel-related morbidity, healthcare providers should be prepared to give travel advice to parents of VFR infants and children, particularly those US-born VFRs with foreign-born parents, regarding antimalarial and antidiarrheal medications and preventing yellow fever, malaria and typhoid.
BACKGROUND: The study objective was to assess differences in demographics and travel health challenges between youths ≤18 years old traveling internationally to visit friends and relatives (VFRs) compared with those traveling for other purposes (non-VFR). METHODS: The Boston Area Travel Medicine Network consists of 5 clinics collecting anonymous data from international pretravel consultations. Data on all travelers ≤18 years of age seen between January 2008 and July 2010 were used. VFRs were compared with non-VFRs on demographics, primary language, trip characteristics, travel vaccinations administered, malaria prophylaxis and antidiarrheal medications prescribed. RESULTS: Thirty-five percent (610/1731) listed VFR as their purpose of travel. Almost half of VFRs were <5 (46%) years old compared with <5% of non-VFRs. Thirty percent of US-born VFRs with foreign-born parents were ≤2 years compared with 4% of foreign-born VFR children and 3% of US-born VFRs with US-born parents. More VFRs than non-VFRs planned travel to countries that were yellow fever holoendemic, had malaria risk and were high-risk for typhoid (44% versus 20%, 39% versus 12%, 25% versus 15%, P < 0.01). VFRs were less likely than non-VFRs to be prescribed atovaquone-proguanil (adjusted prevalence ratio = 0.57, confidence interval = 0.44-0.72) and to have had an antidiarrheal medication prescribed (adjusted prevalence ratio = 0.68, confidence interval = 0.60-0.75). CONCLUSIONS: To reduce travel-related morbidity, healthcare providers should be prepared to give travel advice to parents of VFR infants and children, particularly those US-born VFRs with foreign-born parents, regarding antimalarial and antidiarrheal medications and preventing yellow fever, malaria and typhoid.
Authors: Brian Aw; Suni Boraston; David Botten; Darin Cherniwchan; Hyder Fazal; Timothy Kelton; Michael Libman; Colin Saldanha; Philip Scappatura; Brian Stowe Journal: Can Fam Physician Date: 2014-12 Impact factor: 3.275
Authors: David P Ashley; Jamie Fraser; Heather Yun; Anjali Kunz; Mary Fairchok; David Tribble; Indrani Mitra; Mark D Johnson; Patrick W Hickey; Anuradha Ganesan; Robert G Deiss; Tahaniyat Lalani Journal: Am J Trop Med Hyg Date: 2019-05 Impact factor: 2.345
Authors: Kashmira A Date; Anna E Newton; Felicita Medalla; Anna Blackstock; LaTonia Richardson; Andre McCullough; Eric D Mintz; Barbara E Mahon Journal: Clin Infect Dis Date: 2016-04-18 Impact factor: 9.079
Authors: Stefan H F Hagmann; Kristina M Angelo; Ralph Huits; Katherine Plewes; Gilles Eperon; Martin P Grobusch; Anne McCarthy; Michael Libman; Eric Caumes; Daniel T Leung; Hilmir Asgeirsson; Mogens Jensenius; Eli Schwartz; Adrian Sánchez-Montalvá; Paul Kelly; Prativa Pandey; Karin Leder; Daniel L Bourque; Yukihiro Yoshimura; Frank P Mockenhaupt; Perry J J van Genderen; Silvia Odolini; Patricia Schlagenhauf; Bradley A Connor; Davidson H Hamer Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191
Authors: A E Heywood; N Zwar; B L Forssman; H Seale; N Stephens; J Musto; C Lane; B Polkinghorne; M Sheikh; M Smith; H Worth; C R Macintyre Journal: Epidemiol Infect Date: 2016-08-30 Impact factor: 2.451
Authors: Davidson H Hamer; William B MacLeod; Lin H Chen; Natasha S Hochberg; Laura Kogelman; Adolf W Karchmer; Winnie W Ooi; Christine Benoit; Mary E Wilson; Emily S Jentes; Elizabeth D Barnett Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2017-04-28